
Pubmed-entry ::= {
  pmid 29131988,
  medent {
    em std {
      year 2017,
      month 11,
      day 14,
      hour 6,
      minute 0
    },
    cit {
      title {
        name "Treatment adoption and relative effectiveness of aromatase
 inhibitors compared to tamoxifen in early breast cancer: A
 multi-institutional observational study."
      },
      authors {
        names std {
          {
            name ml "Ferreira AR",
            affil str "Hospital de Santa Maria, Centro Hospitalar de Lisboa
 Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal; Instituto de Medicina
 Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas
 Moniz, 1649-035 Lisbon, Portugal."
          },
          {
            name ml "Palha A",
            affil str "Hospital de Santa Maria, Centro Hospitalar de Lisboa
 Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal."
          },
          {
            name ml "Correia L",
            affil str "Hospital de Santa Maria, Centro Hospitalar de Lisboa
 Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal."
          },
          {
            name ml "Filipe P",
            affil str "Hospital de Santa Maria, Centro Hospitalar de Lisboa
 Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal."
          },
          {
            name ml "Rodrigues V",
            affil str "Hospital de Santa Maria, Centro Hospitalar de Lisboa
 Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal."
          },
          {
            name ml "Miranda A",
            affil str "Registo Oncologico Regional do Sul, Instituto Portugues
 de Oncologia F. G. de Lisboa, R. Prof. Lima Basto, 1099-023 Lisbon, Portugal."
          },
          {
            name ml "Andre R",
            affil str "Registo Oncologico Regional do Sul, Instituto Portugues
 de Oncologia F. G. de Lisboa, R. Prof. Lima Basto, 1099-023 Lisbon, Portugal."
          },
          {
            name ml "Fernandes J",
            affil str "Hospitais CUF Lisboa, R. Mario Botas, 1998-018 Lisbon,
 Portugal."
          },
          {
            name ml "Gouveia J",
            affil str "Hospitais CUF Lisboa, R. Mario Botas, 1998-018 Lisbon,
 Portugal."
          },
          {
            name ml "Passos-Coelho JL",
            affil str "Hospital da Luz, Avenida Lusiada, 100, 1500-650 Lisbon,
 Portugal."
          },
          {
            name ml "Moreira A",
            affil str "Instituto Portugues de Oncologia F. G. de Lisboa, R.
 Prof. Lima Basto, 1099-023 Lisbon, Portugal."
          },
          {
            name ml "Brito M",
            affil str "Instituto Portugues de Oncologia F. G. de Lisboa, R.
 Prof. Lima Basto, 1099-023 Lisbon, Portugal."
          },
          {
            name ml "Ribeiro J",
            affil str "Fundacao Champalimaud, Av. Brasilia, 1400-038 Lisbon,
 Portugal."
          },
          {
            name ml "Metzger-Filho O",
            affil str "Dana-Farber Cancer Institute, 450 Brookline Ave,
 Boston, MA 02215, USA."
          },
          {
            name ml "Lin NU",
            affil str "Dana-Farber Cancer Institute, 450 Brookline Ave,
 Boston, MA 02215, USA."
          },
          {
            name ml "Costa L",
            affil str "Hospital de Santa Maria, Centro Hospitalar de Lisboa
 Norte, Av. Prof. Egas Moniz, 1649-035 Lisbon, Portugal; Instituto de Medicina
 Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas
 Moniz, 1649-035 Lisbon, Portugal."
          },
          {
            name ml "Vaz-Luis I",
            affil str "Institut Gustave Roussy, Unit INSERM 981, 114 Rue
 Edouard Vaillant, 94800 Villejuif, France; Dana-Farber Cancer Institute, 450
 Brookline Ave, Boston, MA 02215, USA. Electronic address:
 Ines-Maria.Vaz-Duarte-Luis@gustaveroussy.fr."
          }
        }
      },
      from journal {
        title {
          iso-jta "Breast",
          ml-jta "Breast",
          issn "1532-3080",
          name "Breast (Edinburgh, Scotland)"
        },
        imp {
          date std {
            year 2018,
            month 2
          },
          volume "37",
          pages "107-113",
          language "eng",
          pubstatus ppublish,
          history {
            {
              pubstatus received,
              date std {
                year 2017,
                month 6,
                day 12
              }
            },
            {
              pubstatus revised,
              date std {
                year 2017,
                month 10,
                day 18
              }
            },
            {
              pubstatus accepted,
              date std {
                year 2017,
                month 11,
                day 3
              }
            },
            {
              pubstatus pubmed,
              date std {
                year 2017,
                month 11,
                day 14,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus medline,
              date std {
                year 2018,
                month 8,
                day 1,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus other,
              date std {
                year 2017,
                month 11,
                day 14,
                hour 6,
                minute 0
              }
            }
          }
        }
      },
      ids {
        pubmed 29131988,
        pii "S0960-9776(17)30773-7",
        doi "10.1016/j.breast.2017.11.003",
        other {
          db "ELocationID pii",
          tag str "S0960-9776(17)30773-7"
        },
        other {
          db "ELocationID doi",
          tag str "10.1016/j.breast.2017.11.003"
        }
      }
    },
    abstract "BACKGROUND: Since 2005, aromatase inhibitors (AIs) have been the
 adjuvant treatment of choice for postmenopausal women with early breast
 cancer (BC). In this study we characterize the adoption of AIs in Portugal,
 variables associated with treatment administration, and compare its
 effectiveness (either in monotherapy or sequential therapy) to tamoxifen
 monotherapy (TAM). PATIENTS AND METHODS: This was a retrospective cohort
 study that included postmenopausal women with stage I-III hormone receptor
 (HR) positive BC diagnosed from 2006 to 2008 and treated with adjuvant
 endocrine therapy in four participating institutions. RESULTS: Of the 1283
 eligible patients, 527 (41%) received an AI (16% as monotherapy, 25% as
 sequential therapy) and 756 (59%) TAM. Patients treated with AI had less
 differentiated tumors, with higher TNM stage, and were more frequently
 HER2-positive. Use of AI also differed by center (use range from 33% to 75%,
 p < 0.001). With a median follow-up of 6.3 years and controlling for
 clinicopathological and treatment characteristics, treatment with AI had a
 better overall survival (OS) when compared with TAM (adjusted-HR 0.55, 95% CI
 0.37-0.81). CONCLUSION: AIs were successfully introduced as adjuvant
 treatment for HR-positive BC in Portuguese hospitals. Its use was influenced
 by tumor and patient characteristics, but also center of care. In this large
 cohort, AI use was associated with an OS benefit.",
    mesh {
      {
        term "Aged"
      },
      {
        term "Antineoplastic Agents, Hormonal",
        qual {
          {
            mp TRUE,
            subh "therapeutic use"
          }
        }
      },
      {
        term "Antineoplastic Combined Chemotherapy Protocols",
        qual {
          {
            subh "therapeutic use"
          }
        }
      },
      {
        term "Aromatase Inhibitors",
        qual {
          {
            subh "administration & dosage"
          },
          {
            mp TRUE,
            subh "therapeutic use"
          }
        }
      },
      {
        term "Breast Neoplasms",
        qual {
          {
            mp TRUE,
            subh "drug therapy"
          },
          {
            subh "metabolism"
          },
          {
            mp TRUE,
            subh "pathology"
          }
        }
      },
      {
        term "Female"
      },
      {
        term "Humans"
      },
      {
        term "Lymphatic Metastasis"
      },
      {
        term "Middle Aged"
      },
      {
        term "Neoplasm Grading"
      },
      {
        term "Neoplasm Staging"
      },
      {
        term "Portugal"
      },
      {
        term "Receptor, ErbB-2",
        qual {
          {
            subh "metabolism"
          }
        }
      },
      {
        term "Receptors, Estrogen",
        qual {
          {
            subh "metabolism"
          }
        }
      },
      {
        term "Receptors, Progesterone",
        qual {
          {
            subh "metabolism"
          }
        }
      },
      {
        term "Survival Rate"
      },
      {
        term "Tamoxifen",
        qual {
          {
            subh "administration & dosage"
          },
          {
            mp TRUE,
            subh "therapeutic use"
          }
        }
      }
    },
    substance {
      {
        type nameonly,
        name "Antineoplastic Agents, Hormonal"
      },
      {
        type nameonly,
        name "Aromatase Inhibitors"
      },
      {
        type nameonly,
        name "Receptors, Estrogen"
      },
      {
        type nameonly,
        name "Receptors, Progesterone"
      },
      {
        type cas,
        cit "094ZI81Y45",
        name "Tamoxifen"
      },
      {
        type ec,
        cit "2.7.10.1",
        name "ERBB2 protein, human"
      },
      {
        type ec,
        cit "2.7.10.1",
        name "Receptor, ErbB-2"
      }
    },
    pmid 29131988,
    pub-type {
      "Comparative Study",
      "Journal Article",
      "Multicenter Study",
      "Observational Study"
    },
    status medline
  }
}


